32 completed, 8 recruiting, 5 active not recruiting, 4 not yet recruiting. 31 Phase 2, 11 Phase 1, 5 Not applicable, 4 Phase 3, 1 Phase 4.
Follow Endometrial Adenocarcinoma: new trials by email Literature Review of Endometrial Adenocarcinoma trials Research Report on Endometrial Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer anti-PD1 agent therapy - 1 year, anti-PD1 agent therapy - 2 years - Endometrial Adenocarcinoma, Metastatic Endometrial Cancer | Phase 3 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 140 | 2026-10-01 | 2026-10-15 |
| DBC-664 in Adult Patients With Solid Tumors DBC-664 - Malignant Germ Cell Tumor, Lung Adenocarcinoma | Phase 1 | Recruiting | Duboce Biopharmaceuticals, Inc. | 210 | 2026-07-17 | 2026-09-29 |
| Comparison of Sentinel Lymph Node Applications in Endometrial Cancer Cases Performed With Vaginal Natural Orifice Transluminal Endoscopic Surgery (V-NOTES) and Conventional Laparoscopy Endometrial Adenocarcinoma, Endometrial Cancer | Not yet recruiting | Cukurova University | 160 | 2026-05-19 | 2026-05-20 | |
| Prognosis of METTL-14 in Endometrial Carcinoma Observation, IHC - Endometrial Cancer, Endometrial Adenocarcinoma | Not yet recruiting | Assiut University | 50 | 2025-09-27 | 2025-09-30 | |
| Surgical and Obstetric Outcomes in Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia With Conservative Treatment Hysteroscopic Resection and Hormonal Therapy - Endometrial Adenocarcinoma, Endometrial Hyperplasia | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 100 | 2025-06-20 | 2025-07-22 | |
| QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer QL1706 combined with chemotherapy ± Bevacizumab - Endometrial Adenocarcinoma, Endometrial Cancer | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2025-06-16 | 2026-10-16 |
| Clonal Hematopoiesis Chemotherapy and Radiation Effects Study Samples - Lung Cancer (Diagnosis), Osteochondroma | Recruiting | Dana-Farber Cancer Institute | 5000 | 2025-04-04 | 2026-06-30 | |
| Safety, Efficacy and Quality of Life After Adjuvant Hypofractionated Radiotherapy for Endometrial Cancer Hypo fractionated RT - Endometrial Cancer, Endometrial Adenocarcinoma | Not applicable | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 50 | 2025-03-07 | 2026-10-13 |
| A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors APL-5125 - Colorectal Cancer, Cholangiocarcinoma | Phase 1 | Completed | Apollo Therapeutics Ltd | 27 | 2024-06-18 | 2026-10-05 |
| Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer Cadonilimab, Carboplatin, Cisplatin - Endometrial Cancer, Endometrial Adenocarcinoma | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 45 | 2024-02-01 | 2024-01-23 |
| Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer Cadonilimab, Lenvatinib - Endometrial Cancer, Endometrial Adenocarcinoma | Phase 2 | Active not recruiting | Sun Yat-sen University | 32 | 2023-05-08 | 2026-03-10 |
| AMT-151 in Patients With Selected Advanced Solid Tumours AMT-151 - Advanced Solid Tumor, Advanced Cancer | Phase 1 | Unknown | Multitude Therapeutics Inc. | 30 | 2023-01-25 | 2023-10-19 |
| A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma ACR-368, Gemcitabine, OncoSignature - Endometrial Adenocarcinoma | Phase 2 | Recruiting | Acrivon Therapeutics | 350 | 2022-08-29 | 2026-08-21 |
| V-Notes Hysterectomy in Patients With Endometrial cáncer Compared With Laparoscopic Surgery (Robotically Assisted or Not): ENOLA TRIAL Laparoscopic surgery, surgery via v-NOTES - Endometrial Adenocarcinoma | Not applicable | Completed | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | 84 | 2022-07-11 | 2025-07-20 |
| Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma Biospecimen Collection, Computed Tomography, Ipilimumab - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 81 | 2022-06-02 | 2026-10-21 |
| PErsonalized TReatment for Endometrial Carcinoma Comparison of chemotherapy vs. chemoradiotherapy, Comparison of VBT vs. WPRT - Endometrial Adenocarcinoma | Not applicable | Recruiting | University of Helsinki | 300 | 2022-02-08 | 2024-12-06 |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) ELU001 - Ovarian Cancer, Ovarian Neoplasms | Phase 1 / Phase 2 | Terminated | Elucida Oncology | 79 | 2021-09-13 | 2024-08-07 |
| [SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer Laparoscopic total hysterectomy with bilateral salpingo-oophorectomy and sentinel lymph node biopsy - Endometrial Cancer, Endometrial Neoplasms | Not applicable | Completed | Moscow City Oncology Hospital No. 62 | 102 | 2021-07-01 | 2024-05-07 |
| Diagnostic and Prognostic Value of PTEN Expression in Functional and Pathological Endometrial Biopsies routine stain by H&E. - Endometrial Hyperplasia, Endometrial Adenocarcinoma | Completed | Sohag University | 80 | 2020-01-01 | 2022-07-15 | |
| Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment Nivolumab, BMS- 986205 - Endometrial Adenocarcinoma, Endometrial Carcinosarcoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 24 | 2019-09-24 | 2026-10-16 |
Showing 20 of 56. Sign in to see all of them.
Endometrial Neoplasms (23) · Ovarian Neoplasms (6) · Carcinoma, Endometrioid (4) · Endometrial Hyperplasia (4) · Fallopian Tube Neoplasms (4) · Carcinoma (3) · Triple Negative Breast Neoplasms (3) · Adenocarcinoma of Lung (2) · Breast Neoplasms (2) · Carcinoma, Ovarian Epithelial (2) · Neoplasms (2) · Recurrence (2) · Stomach Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma Of Esophagus (1)
Neoplasms by Site (31) · Female Urogenital Diseases (30) · Female Urogenital Diseases and Pregnancy Complications (30) · Genital Diseases (30) · Genital Diseases, Female (30) · Neoplasms (30) · Urogenital Diseases (30) · Genital Neoplasms, Female (29) · Urogenital Neoplasms (29) · Uterine Neoplasms (26) · Uterine Diseases (24) · Neoplasms by Histologic Type (11) · Adnexal Diseases (9) · Endocrine System Diseases (9) · Gonadal Disorders (9)
Paclitaxel (9) · Carboplatin (7) · Taxes (7) · Cisplatin (5) · Bevacizumab (3) · Disulfides (3) · Immunoglobulin G (3) · Doxorubicin (2) · Gemcitabine (2) · Laparoscopy (2) · Megestrol Acetate (2) · Metformin (2) · Nivolumab (2) · Sirolimus (2) · Specimen Handling (2)
National Cancer Institute (NCI) (14) · Gynecologic Oncology Group (12) · Assiut University (2) · M.D. Anderson Cancer Center (2) · Acrivon Therapeutics (1) · Albert Einstein College of Medicine (1) · Apollo Therapeutics Ltd (1) · Cukurova University (1) · Dana-Farber Cancer Institute (1) · Daniela Matei, MD (1) · Duboce Biopharmaceuticals, Inc. (1) · Elucida Oncology (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Fudan University (1) · Fujian Cancer Hospital (1)
United States (39) · Canada (5) · China (5) · Egypt (3) · Italy (2) · Spain (2) · Australia (1) · Finland (1) · France (1) · Germany (1) · Hong Kong (1) · Russia (1) · Turkey (Türkiye) (1)
Don Dizon (3) · Shannon N Westin (3) · Robert Coleman (2) · Akila Viswanathan (1) · Amit M Oza (1) · Amit Oza (1) · Anish Thomas, MD (1) · Carol Aghajanian (1) · Catherine Shannon (1) · Chao Wang, Ph.D. (1) · Chrisann Kyi, MD (1) · D. Scott McMeekin (1) · Daniela Matei, M.D. (1) · David Bender (1) · David Tait (1)
PMID 32379297, PMID 24882554, PMID 25312396, PMID 25847373, PMID 25887099, PMID 29037481, PMID 31714586, PMID 33541735, PMID 35658479, PMID 37813479, PMID 38127487, PMID 38697821, PMID 40389320, PMID 41528970, PMID 42000370, PMID 42838953
U10CA027469 (19), U10CA180868 (11), P50CA098258 (2), 2025 (1), N01CM62201 (1), N01CM62203 (1), N01CM62209 (1), P30CA006516 (1), P30CA013330 (1), P30CA014089 (1), P30CA016672 (1), P50CA083639 (1), U01CA062490 (1), U10CA021661 (1), U10CA180830 (1)